Please login to the form below
Wilson Therapeutics
This page shows the latest Wilson Therapeutics news and features for those working in and with pharma, biotech and healthcare.
AZ’s new rare disease unit wins in Wilson disease
Alexion purchase looks increasingly ‘copper-bottomed’ as AstraZeneca prepares to submit data for ALXN1840 in Wilson disease. ... ALXN1840 was first discovered at Stockholm-based Wilson Therapeutics, a company named after the genetic disorder it
Latest news
-
Alexion eyes Soliris combo with $930m deal to buy Achillion
Other bolt-on deals to boost its product portfolio and pipeline include the $1.2bn takeover of Syntimmune and $855m purchase of Wilson Therapeutics last year.
-
Pfizer goes big on gene therapy with $500m facility spend
That was followed swiftly by a partnership with Spark Therapeutics that brought in a clinical-stage haemophilia B therapy now in phase 3 testing, and another deal with Sangamo for a ... It also took a 15% stake in Vivet Therapeutics and its lead
-
Alexion targets RNAi with $637m Dicerna deal
The new deal adds to others made by Alexion this year, including the $855m acquisition of rare disease company Wilson Therapeutics in April and privately-held autoimmune disease specialists Syntimmune in
-
Alexion adds to pipeline with $1.2bn Syntimmune buy
In the meantime, however, it’s also been adding to its earlier-stage pipeline and the Syntimmune acquisition comes a few months after it snapped up Swedish biotech Wilson Therapeutics for ... $855m, adding orally-active copper binder WTX-101 in phase
-
Abingworth raises $315m to expand hunt for promising biotechs
The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... Abingworth has shown it is prepared to back
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
Latest appointments
-
IGEM Therapeutics appoints Dr Tim Wilson as CEO
Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research. ... Wilson has worked for numerous private and public life science companies in the US and Europe at
-
Therachon strengthens management team
He currently serves as chairman of Asceneuron, Complix and InteRNA, and as a non-executive director at Hansa Medical, Sobi, Wilson Therapeutics and Dutch Top Sector Life Sciences and Health.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Actinic keratosis – a common skin condition that can lead to skin cancer
- The paper trail
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
No results were found
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
